News Sentiment

TECH sentiment intelligence

Bio-Techne Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 25 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 71.30 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 17

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.7% over one week, +32.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

SK Hynix shares surge 13% on AI hopes as US tech stocks resume their climb

Market Reaction

Balanced read

52/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive 32.0% over four weeks
Fair value 10.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 13
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 17
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
TradingView 3
simplywall.st 3
Investing.com 2
Reuters 1
DirectorsTalk Interviews 1
marketscreener.com 1
Investing News Network 1

Event Lens

What the news is about

Classified themes
Market update 11
Earnings 10
Deals and strategy 2
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-25 of 25
DirectorsTalk Interviews Direct company coverage

Bio-Techne Corp (TECH) Stock Analysis: Navigating the Biotechnology Landscape Amidst Revenue Challenges

Bio-Techne Corp (NASDAQ: TECH) is a significant player in the biotechnology sector, specializing in life science reagents, instruments, and services, with a market capitalization of $11.11 billion. Despite its near annual high stock price and robust free cash flow, the company fa

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 01:41
Source
DirectorsTalk Interviews
TradingView Direct company coverage

Enterprise value to EBITDA forward of Bio-Techne Corporation – DUS:TE1

This article provides financial data for Bio-Techne Corporation (DUS:TE1) focusing on its enterprise value to EBITDA for the forward period. It lists the company on the Dusseldorf Stock Exchange and indicates general market status and available financial information.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 00:08
Source
TradingView
marketscreener.com Direct company coverage

RBC Capital Downgrades Bio-Techne to Sector Perform From Outperform, Adjusts Price Target to $73 From $62

RBC Capital has downgraded Bio-Techne (NASDAQ: TECH) from an "Outperform" rating to "Sector Perform." The firm also adjusted its price target for Bio-Techne shares, raising it to $73 from $62. This comes amidst a series of recent analyst downgrades for Bio-Techne.

Tone
Negative 36/100
Event
Analyst action
Published
09 Jul 2026 07:25
Source
marketscreener.com
Investing News Network Direct company coverage

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

Bio-Techne Corporation (NASDAQ: TECH) has expanded its R&D Systems AI-Engineered Designer Protein portfolio with new heat-stable and hyperactive proteins. These additions are designed to improve reproducibility, consistency, and scalability in advanced cell culture and cell thera

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 02:08
Source
Investing News Network
Pluang Direct company coverage

Bio-Techne launches AI-designed proteins to boost cell therapy consistency and scalability

Bio-Techne Corporation has launched new AI-engineered proteins designed to improve reproducibility and performance in cell therapy workflows. These proteins, including heat-stable fibroblast growth factors and hyperactive interleukins, aim to enhance stability and activity, addre

Tone
Positive 85/100
Event
Market update
Published
08 Jul 2026 12:38
Source
Pluang
TradingView Direct company coverage

Enterprise value to EBITDA forward of Bio-Techne Corporation – MUN:TE1

The article focuses on the "Enterprise value to EBITDA forward" financial metric for Bio-Techne Corporation (MUN:TE1) on the Munich Stock Exchange. It provides a snapshot that the market is closed and no trades have occurred for this specific data point, which is part of a larger

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 11:38
Source
TradingView
Investing.com Direct company coverage

Bio-Techne expands AI-engineered protein portfolio for cell therapy

Bio-Techne Corporation has launched five new AI-engineered designer proteins, including FGF-4, FGF-7, FGF-8b, IL-3 Heat Stable, and IL-15 Hyperactive proteins, to enhance cell culture and cell therapy applications by improving stability and activity. These proteins are designed f

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Investing.com
Investing.com South Africa Direct company coverage

Bio-Techne expands AI-engineered protein portfolio for cell therapy By Investing.com

Bio-Techne Corporation announced the expansion of its R&D Systems AI-Engineered Designer Protein portfolio with five new proteins targeted at cell culture and cell therapy applications. These proteins, including heat-stable FGF and IL proteins, are engineered for enhanced stabili

Tone
Positive 66/100
Event
Market update
Published
08 Jul 2026 10:38
Source
Investing.com South Africa
Stock Titan Direct company coverage

Bio-Techne expands designer proteins for cell therapy and organoids

Bio-Techne (NASDAQ:TECH) has launched new R&D Systems AI-Engineered Designer Proteins, expanding its portfolio for advanced cell culture and cell therapy workflows. The additions include heat-stable fibroblast growth factors (FGF-4, FGF-7, FGF-8b) and hyperactive cytokines (IL-3,

Tone
Positive 65/100
Event
Market update
Published
08 Jul 2026 10:29
Source
Stock Titan
Investing.com Canada Direct company coverage

Form DEF 14A Bio-Techne Corp For: 7 July By Investing.com

This article announces the filing of Form DEF 14A by Bio-Techne Corp on July 7, 2026. The content provides basic financial market data, including various indices, commodities, and stock performances, alongside a brief mention of the specific SEC filing for Bio-Techne.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:37
Source
Investing.com Canada
Supply Chain Digital Direct company coverage

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)

Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of LCI Industries (LCII), Iridium Communications Inc. (IRDM), Bio-Techne Corporation (TECH), and Arcosa, Inc. (ACA) regarding their proposed acquisitions. The investigations focus o

Tone
Negative 36/100
Event
Deals and strategy
Published
07 Jul 2026 00:38
Source
Supply Chain Digital
GlobeNewswire Direct company coverage

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of

Brodsky & Smith LLC is notifying investors of investigations into four companies: LCI Industries (LCII), Iridium Communications Inc. (IRDM), Bio-Techne Corporation (TECH), and Arcosa, Inc. (ACA). The investigations concern potential breaches of fiduciary duties by the companies'

Tone
Negative 39/100
Event
Regulatory and legal
Published
06 Jul 2026 16:17
Source
GlobeNewswire